Exchange & Returns Information
Review Details
(30)
| Drug Type | Original |
|---|---|
| Active Ingredient | SEMAGLUTIDE |
| Strength | 1MG |
| Manufacturer | NOVO NORDISK |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 PEN | $ 360.00 | $ 360.00 |
$ 302.40
Apply WEGO26 (-16%)
You save $ 57.60
|
||
| 2 BOXES - 2 PENS | $ 299.50 |
17% $ 720.00
$ 599.00
|
$ 503.16
Apply WEGO26 (-16%)
You save $ 95.84
|
||
| ★ Best Value 3 BOXES - 3 PENS | $ 253.00 |
30% $ 1,080.00
$ 759.00
|
$ 637.56
Apply WEGO26 (-16%)
You save $ 121.44
|
Reference information will be available soon.
Wegovy 1mg Flextouch Pen is a once-weekly, prefilled subcutaneous injection containing semaglutide, a long-acting GLP-1 receptor agonist specifically approved for the treatment of obesity. By mimicking endogenous glucagon-like peptide-1, it regulates multiple metabolic pathways, including enhancing insulin secretion (when blood glucose is elevated), suppressing glucagon, and delaying gastric emptying. These mechanisms work synergistically to reduce appetite, prolong satiety, and decrease overall caloric intake. While semaglutide is used off-label for type 2 diabetes control in some formulations, Wegovy is not approved for glycemic management and must be used exclusively as a weight loss therapeutic. This 1mg dose represents an intermediate step in the titration protocol, preparing patients for the final maintenance dose of 2.4mg.
- DIET (Metabolic Weight Control) > Indicated for long-term weight management in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one comorbidity such as hypertension, dyslipidemia, or T2DM. Wegovy acts by modifying central appetite pathways and gastrointestinal motility, helping users sustain dietary adherence and achieve meaningful fat loss without stimulants or amphetamine-like compounds. - DIABETES (GLP-1 Receptor Agonists) > Although semaglutide is commonly used off-label to support glucose regulation in people with type 2 diabetes, Wegovy itself is not indicated for this purpose. Its GLP-1 receptor agonism may offer secondary glycemic benefits in overweight patients, but its clinical role remains confined to obesity therapy.
Semaglutide exerts its pharmacological effects by binding to GLP-1 receptors in the pancreas, gastrointestinal tract, and hypothalamus. This action promotes insulin release only when glucose levels are elevated, inhibits glucagon secretion, and slows gastric emptying to reduce post-meal glucose surges. In terms of appetite regulation, it enhances satiety signaling in the brain, contributing to a decreased desire to eat. As a non-stimulant hormonal therapy, Wegovy enables gradual and sustained weight reduction without cardiovascular overstimulation or abrupt energy crashes. The 1mg dose helps patients transition toward higher therapeutic concentrations with reduced gastrointestinal side effects.
→ Chronic Weight Management Schedule (Wegovy-specific): - Week 1–4: 0.25 mg SC once weekly - Week 5–8: 0.5 mg SC once weekly - Week 9–12: 1.0 mg SC once weekly *(This product corresponds to this stage)* - Week 13–16: 1.7 mg SC once weekly - Week 17 and beyond: 2.4 mg SC once weekly (maintenance dose) → Dose Adjustment Protocol: - If gastrointestinal intolerance occurs, delay dose escalation by 4 additional weeks - If 2.4 mg dose is not tolerated: reduce to 1.7 mg/week for up to 4 weeks, then retry 2.4 mg - Therapy should be discontinued if 2.4 mg remains consistently intolerable → Use Criteria: - Adults with BMI ≥30 kg/m² (obesity), or - Adults with BMI ≥27 kg/m² with at least one weight-related risk factor (e.g., hypertension, dyslipidemia, insulin resistance) → Administration Guidelines: - Inject subcutaneously once per week, preferably on the same day - Rotate injection sites between abdomen, thigh, or upper arm - Do not co-administer with any other GLP-1 agonist or semaglutide-containing product → Off-Label Use (T2DM Context): - In some cases, a 1mg dose is used off-label to support glycemic control in obese adults with type 2 diabetes - Switching from oral semaglutide (14 mg) to SC: begin with 0.5 mg SC; titrate to 1.0 mg if needed - Note: There is no approved oral dose equivalent to 1.0 mg SC
Store refrigerated between 2–8°C until first use. Do not freeze. Once in use, pens can be stored at room temperature (up to 30°C) for up to 28 days. Keep pen capped and away from direct sunlight. Ensure out-of-reach storage for children.
Gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation are the most frequently reported adverse reactions. These are generally dose-dependent and transient, often resolving as the patient adapts to therapy. Serious adverse reactions may include pancreatitis, acute gallbladder events, or kidney injury secondary to dehydration. While the risk of hypoglycemia is low when Wegovy is used alone, it increases when combined with insulin or sulfonylureas. Patients should be advised to seek immediate medical attention for signs of persistent abdominal pain, severe vomiting, or allergic reactions.
After a month on the 1mg dose, the changes are becoming more apparent in my daily life. My favorite jeans fit comfortably again, I can walk up a flight of stairs without feeling winded, and I have more energy to play with my kids. These are the victories that truly matter. The Wegovy is clearly working as a tool to help me achieve these lifestyle improvements. The easy, discreet ordering process from this site makes it one less thing to worry about.
Three orders in, and the experience has been perfect every time. Cold-chain shipping is always on point.
Happy with my purchase.
The quality of their cold-chain shipping is consistently excellent.
I'm always impressed by how quickly and professionally my orders are handled.
No combo deals available at the moment.
